The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cited by
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Self-citationRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Self-citationMonocyte chemoattractant protein 1 in obesity and insulin resistance
Sartipy, P., & Loskutoff, D. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133870100 · Cited by 1,201
The Insulin-Related Ovarian Regulatory System in Health and Disease
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., & Giudice, L. C. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0374 · Cited by 818
Obesity and the polycystic ovary syndrome
Gambineri, A., Pelusi, C., Vicennati, V, Pagotto, U., & Pasquali, R. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801994 · Cited by 836
Nestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 784
Legro, R. S., Finegood, D., & Dunaif, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5054 · Cited by 673
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Calles-Escandon, J., & Cipolla, M. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0417 · Cited by 657
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists
Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10843 · Cited by 537
Azziz, R., Ehrmann, D., Legro, R. S., Whitcomb, R. W., Hanley, R., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7375 · Cited by 517
Self-citationRosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518
Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction
Paradisi, G., Steinberg, H. O., Hempfling, A., Cronin, J., Hook, G., Shepard, M. K., & Baron, A. D. (2001) · Circulation · doi:10.1161/01.cir.103.10.1410 · Cited by 475
Role of Hormones in Pilosebaceous Unit Development
Deplewski, D., & Rosenfield, R. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0404 · Cited by 443
Self-citationThiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428
The mode of action of thiazolidinediones
Hauner, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.249 · Cited by 411
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Escobar-Morreale, H. F., Luque-Ramírez, M., & San Millán, J. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0004 · Cited by 422
Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 426
Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415
Nonhypoglycemic Effects of Thiazolidinediones
Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 412
Cavaghan, M. K., Ehrmann, D. A., & Polonsky, K. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10761 · Cited by 362
Self-citationMarx, N., Bourcier, T., Sukhova, G. K., Libby, P., & Plutzky, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.546 · Cited by 362
Ovulation induction in the management of anovulatory polycystic ovary syndrome
Balen, A. H. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.008 · Cited by 347
“The insulin-sensitizing agent troglitazone also appeared to significantly improve the metabolic and reproductive abnormalities in PCOS (Ehrmann et al., 1997), although this product has been withdrawn because of reports of fatal liver damage.”
Sex steroids and insulin resistance
LIVINGSTONE, C., & COLLISON, M. (2002) · Clinical Science · doi:10.1042/cs1020151 · Cited by 309
The Importance of Diagnosing the Polycystic Ovary Syndrome
Lobo, R. A., & Carmina, E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-12-200006200-00010 · Cited by 309
The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Blank, S. K., McCartney, C. R., & Marshall, J. C. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml017 · Cited by 301
Baillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300
Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
Lewy, V. D., Danadian, K., Witchel, S. F., & Arslanian, S. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109603 · Cited by 298
The pathophysiology of polycystic ovary syndrome
Tsilchorozidou, T., Overton, C., & Conway, G. S. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01842.x · Cited by 294
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Dellas, C., & Loskutoff, D. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0033 · Cited by 285
PPARγ and the Treatment of Insulin Resistance
OLEFSKY, J., & SALTIEL, A. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00306-4 · Cited by 279
Insulin resistance and risk for stroke
Kernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., & Horwitz, R. I. (2002) · Neurology · doi:10.1212/wnl.59.6.809 · Cited by 280
Hoeger, K. M., Kochman, L., Wixom, N., Craig, K., Miller, R. K., & Guzick, D. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.104 · Cited by 278
Chang, W. Y., Knochenhauer, E. S., Bartolucci, A. A., & Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.096 · Cited by 285
Polycystic Ovarian Syndrome: Diagnosis and Management
Sheehan, M. T. (2004) · Clinical Medicine & Research · doi:10.3121/cmr.2.1.13 · Cited by 263
Sobel, B. E., Woodcock-Mitchell, J., Schneider, D. J., Holt, R. E., Marutsuka, K., & Gold, H. (1998) · Circulation · doi:10.1161/01.cir.97.22.2213 · Cited by 271
Self-citationArslanian, S. A., Lewy, V., Danadian, K., & Saad, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8398 · Cited by 272
The Adipocyte and Hemostatic Balance in Obesity: Studies of PAI-1
Loskutoff, D. J., & Samad, F. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.1 · Cited by 264
INSULIN ACTION IN THE NORMAL AND POLYCYSTIC OVARY
Franks, S., Gilling-Smith, C., Watson, H., & Willis, D. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70074-8 · Cited by 263
Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome
Harborne, L., Fleming, R., Lyall, H., Norman, J., & Sattar, N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13493-9 · Cited by 256
Kolodziejczyk, B., Duleba, A. J., Spaczynski, R. Z., & Pawelczyk, L. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00501-x · Cited by 255
Brettenthaler, N., De Geyter, C., Huber, P. R., & Keller, U. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031737 · Cited by 247
Metformin has direct effects on human ovarian steroidogenesis
Mansfield, R., Galea, R., Brincat, M., Hole, D., & Mason, H. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04925-7 · Cited by 237
Komar, C. M. (2005) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-3-41 · Cited by 219
Nestler, J. E., Stovall, D., Akhter, N., Iuorno, M. J., & Jakubowicz, D. J. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02963-6 · Cited by 230
Glueck, C. J., Wang, P., Fontaine, R., Tracy, T., & Sieve-Smith, L. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90113-0 · Cited by 230
Should all women with PCOS be treated for insulin resistance?
Marshall, J. C., & Dunaif, A. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.11.036 · Cited by 217
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients
Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., & Simonson, D. C. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.172 · Cited by 215
“Treatment of obese and type 2 diabetic patients with troglitazone can reverse these abnormalities (44,45).”
BackgroundMinge, C. E., Bennett, B. D., Norman, R. J., & Robker, R. L. (2008) · Endocrinology · doi:10.1210/en.2007-1570 · Cited by 210
“Systemically insulin resistance in peripheral tissues is ameliorated, and circulating levels of lipids are lowered (60, 61).”
BackgroundOrtega-González, C., Luna, S., Hernández, L., Crespo, G., Aguayo, P., Arteaga-Troncoso, G., & Parra, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1965 · Cited by 212
Yang, J., & Chen, C. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0342 · Cited by 169
Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones
Carmina, E., Orio, F., Palomba, S., Longo, R. A., Cascella, T., Colao, A., Lombardi, G., Rini, G. B., & Lobo, R. A. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.10.059 · Cited by 200
Hunter, S. J., & Garvey, W. T. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00300-3 · Cited by 200
Inappropriate Gonadotropin Secretion in Polycystic Ovary Syndrome: Influence of Adiposity1
Arroyo, A., Laughlin, G. A., Morales, A. J., & Yen, S. S. C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4377 · Cited by 182
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188
Ajmera, V., Perito, E. R., Bass, N. M., Terrault, N. A., Yates, K. P., Gill, R., Loomba, R., Diehl, A. M., & Aouizerat, B. E. (2017) · Hepatology · doi:10.1002/hep.28776 · Cited by 179
Ghazeeri, G., Kutteh, W. H., Bryer-Ash, M., Haas, D., & Ke, R. W. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04843-4 · Cited by 182
Schäfer, K., Fujisawa, K., Konstantinides, S., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0750fje · Cited by 174
Diamanti-Kandarakis, E., Baillargeon, J.-P., Iuorno, M. J., Jakubowicz, D. J., & Nestler, J. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021528 · Cited by 171
Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin?
Baillargeon, J.-P., & Nestler, J. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1804 · Cited by 169
Qu, F., Wang, F., Yin, R., Ding, G., Elprince, M., Gao, Q., Shi, B., Pan, H.-H., Huang, Y.-T., Jin, M., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0881-4 · Cited by 173
Cardiovascular risk continuum: implications of insulin resistance and diabetes
Hsueh, W. A., & Law, R. E. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00205-8 · Cited by 159
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200006000-00019 · Cited by 158
Nonalcoholic Fatty Liver Disease in Women
Suzuki, A., & Abdelmalek, M. F. (2009) · Women s Health · doi:10.2217/17455057.5.2.191 · Cited by 170
Komar, C. M., Braissant, O., Wahli, W., & Curry, T. E. (2001) · Endocrinology · doi:10.1210/en.142.11.4831 · Cited by 158
Arlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Increased Plasminogen Activator Inhibitor-1 and Vasculopathy: A Reconcilable Paradox
Sobel, B. E. (1999) · Circulation · doi:10.1161/01.cir.99.19.2496 · Cited by 159
Self-citationN-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome
Fulghesu, A. M., Ciampelli, M., Muzj, G., Belosi, C., Selvaggi, L. E., Ayala, G. F., & Lanzone, A. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03133-3 · Cited by 155
Childhood Obesity and Its Impact on the Development of Adolescent PCOS
Anderson, A., Solorzano, C. M. B., & McCartney, C. R. (2014) · Seminars in Reproductive Medicine · doi:10.1055/s-0034-1371092 · Cited by 161
Ganie, M. A., Khurana, M. L., Eunice, M., Gulati, M., Dwivedi, S. N., & Ammini, A. C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031780 · Cited by 162
Insulin Resistance in Nonobese Patients with Polycystic Ovary Syndrome
Toprak, S., Yönem, A., Çakır, B., Güler, S., Azal, Ö., Özata, M., & Çorakçı, A. (2001) · Hormone Research in Paediatrics · doi:10.1159/000049972 · Cited by 154
Glueck, C. J., Wang, P., Fontaine, R. N., Tracy, T., & Sieve-Smith, L. (2001) · Journal of Adolescent Health · doi:10.1016/s1054-139x(01)00202-6 · Cited by 153
Use of metformin in polycystic ovary syndrome
Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.010 · Cited by 180
Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome
Wu, X. K., Zhou, S. Y., Liu, J. X., Pöllänen, P., Sallinen, K., Mäkinen, M., & Erkkola, R. U. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01007-0 · Cited by 149
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
Aso, Y. (2007) · Frontiers in bioscience · doi:10.2741/2285 · Cited by 148
Azziz, R. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61644-6 · Cited by 166
Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice
Griffin, S. J., Little, P. S., Hales, C. N., Kinmonth, A. L., & Wareham, N. J. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/1520-7560(200005/06)16:3<164::aid-dmrr103>3.0.co;2-r · Cited by 402
Calles-Escandón, J., Mirza, S. A., Sobel, B. E., & Schneider, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.290 · Cited by 147
Self-citationAdolescent Anovulation: Maturational Mechanisms and Implications
Rosenfield, R. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1770 · Cited by 162
Self-citationJayagopal, V., Kilpatrick, E. S., Jennings, P. E., Hepburn, D. A., & Atkin, S. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020557 · Cited by 137
Daniels, T. L., & Berga, S. L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4402 · Cited by 137
Romualdi, D., Guido, M., Ciampelli, M., Giuliani, M., Leoni, F., Perri, C., & Lanzone, A. (2003) · Human Reproduction · doi:10.1093/humrep/deg264 · Cited by 144
Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome
Jayagopal, V., Kilpatrick, E. S., Holding, S., Jennings, P. E., & Atkin, S. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0176 · Cited by 140
Effects of Exercise and Nutritional Counseling in Women with Polycystic Ovary Syndrome
Bruner, B., Chad, K., & Chizen, D. (2006) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h06-007 · Cited by 133
Effect of plasminogen activator inhibitor–1 in diabetes mellitus and cardiovascular disease
Lyon, C. J., & Hsueh, W. A. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.014 · Cited by 132
Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
Sepilian, V., & Nagamani, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1376 · Cited by 139
Molecular mechanisms of lipid‐induced insulin resistance in muscle, liver and vasculature
Krebs, M., & Roden, M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00439.x · Cited by 148
Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells
Nicholas, S. B., Kawano, Y., Wakino, S., Collins, A. R., & Hsueh, W. A. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.722 · Cited by 127
Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology
Hopkinson, Z. E., Sattar, N. A., Fleming, R., & Greer, I. A. (1998) · BMJ · doi:10.1136/bmj.317.7154.329 · Cited by 125
Impaired Glucose Tolerance in Pregnant Women With Polycystic Ovary Syndrome
RADON, P. A., MCMAHON, M. J., & MEYER, W. R. (1999) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(99)00252-5 · Cited by 135
Ciampelli, M., Fulghesu, A. M., Cucinelli, F., Pavone, V., Ronsisvalle, E., Guido, M., Caruso, A., & Lanzone, A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90028-8 · Cited by 131
Hayden, J. M., & Reaven, P. D. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200010000-00010 · Cited by 121
The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, Α., & Diamanti‐Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 133
Aromatase inhibitors for the treatment of infertility
Mitwally, M. F., & Casper, R. F. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.353 · Cited by 121
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.